RECRUITING Not applicable ClinicalTrials.gov

Multimodal Analgesic Regimen for Total Hip Arthroplasty: An Initiative to Minimize Postoperative Opioid Use

Sponsor: Henry Ford Health System • ClinicalTrials.gov ID: NCT07672808

Registry updated: 2026-10-07

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

This study examines whether patients undergoing total hip replacement surgery can manage their pain effectively while using fewer opioid pain medications. Participants will be randomly assigned to one of two groups. The first group will receive the standard postoperative pain medication regimen, with all prescriptions sent directly to their pharmacy as usual. The second group will receive the same medications, but their opioid prescription will only be provided as a printed copy rather than being sent directly to the pharmacy, requiring them to choose whether to fill it. All participants will keep a pain journal and complete questionnaires about their medication intake over the first 21 days post-op as well as there function and wellbeing at follow up visits over 3 months. The goal is to determine whether this approach reduces opioid use while still adequately controlling pain after hip replacement surgery.

Interventions

Standard Multimodal Analgesic Regimen with Opioid Prescription (Drug)
Participants receive the standard postoperative multimodal pain regimen following primary total hip arthroplasty. All prescriptions are sent directly to the patient's pharmacy. Opioid consumption tracked via the Michigan Automated Prescription System (MAPS) and patient medication journal. Pain and medication consumption are assessed via daily pain/medication logs daily for the first week, then weekly for two additional weeks.
Opioid-Reduced Multimodal Analgesic Regimen with Printed Prescription (Behavioral)
Participants receive the standard postoperative multimodal pain regimen following primary total hip arthroplasty. Tramadol is prescribed but the prescription is printed and given to the patient rather than sent to the pharmacy, requiring the patient to actively choose to fill it. This behavioral barrier is designed to reduce opioid consumption while preserving patient autonomy. Pain and medication intake is assessed via daily pain journals and medication logs for the first week, then weekly for two additional weeks. Opioid consumption is also tracked via the Michigan Automated Prescription System (MAPS).

Eligibility criteria

Inclusion Criteria: * Adult patients age 18 and older * Patients who have undergone total hip arthroplasty by a single, fellowship trained Orthopaedic Surgeon. Exclusion Criteria: * Patients with incomplete data in medical records * Chronic opioid use in the last 3 months * Ipsilateral joint surgery in the last year * Cannot tolerate oral medications * Swallowing difficulties * Intolerance to Tylenol, Celebrex, Robaxin, Neurontin, or Tramadol * History of Alcohol abuse * History of Drug abuse * History of Renal impairment * History of Peptic ulcer disease * History of GI bleeding * Illicit narcotic usage in past 6 months * Chronic liver disease * Chronic pain syndrome

Conditions

Arthroplasty, Replacement, Hip

Locations

Henry Ford Hospital — Detroit, Michigan, United States

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment